Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Elit

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
European Journal of Gynaecological Oncology|August 25, 2009
Patterns of surgical care for uterine cancers in OntarioL Elit, S Schultz, R Prysbysz, et al.
European Journal of Gynaecological Oncology|November 11, 2009
Patterns of care in the initial management of women with vulvar cancers in OntarioL Elit, S Schultz, R Prysbysz, et al.
Gynecologic Oncology|May 15, 2007
Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guidelineL Elit, L Zitzelsberger, M Fung-Kee-Fung, et al.
European Journal of Gynaecological Oncology|July 4, 2002
Familial and hormonal risk factors for papillary serous uterine cancerL Elit, T Pal, R Goshen, et al.
Clinical Genetics|March 6, 2009
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 geneA Finch, K Metcalfe, J Lui, et al.
Gynecologic Oncology|April 16, 2003
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)A M Oza, L Elit, K Swenerton, et al.
Gynecologic Oncology|January 11, 2011
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutationA Finch, K A Metcalfe, J K Chiang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2011
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)C Kollmannsberger, H Hirte, L L Siu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2011
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trialL Gladieff, A Ferrero, G De Rauglaudre, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 22, 2005
Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignanciesL H Lê, K D Swenerton, L Elit, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
European Journal of Gynaecological Oncology|August 25, 2009
Patterns of surgical care for uterine cancers in OntarioL Elit, S Schultz, R Prysbysz, et al.
European Journal of Gynaecological Oncology|November 11, 2009
Patterns of care in the initial management of women with vulvar cancers in OntarioL Elit, S Schultz, R Prysbysz, et al.
Gynecologic Oncology|May 15, 2007
Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guidelineL Elit, L Zitzelsberger, M Fung-Kee-Fung, et al.
European Journal of Gynaecological Oncology|July 4, 2002
Familial and hormonal risk factors for papillary serous uterine cancerL Elit, T Pal, R Goshen, et al.
Clinical Genetics|March 6, 2009
Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 geneA Finch, K Metcalfe, J Lui, et al.
Gynecologic Oncology|April 16, 2003
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)A M Oza, L Elit, K Swenerton, et al.
Gynecologic Oncology|January 11, 2011
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutationA Finch, K A Metcalfe, J K Chiang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 31, 2011
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)C Kollmannsberger, H Hirte, L L Siu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2011
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trialL Gladieff, A Ferrero, G De Rauglaudre, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 22, 2005
Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignanciesL H Lê, K D Swenerton, L Elit, et al.
Pageof 7